Gene delivery to cartilage defects using coagulated bone marrow aspirate
- 1 January 2004
- journal article
- research article
- Published by Springer Nature in Gene Therapy
- Vol. 11 (2), 133-141
- https://doi.org/10.1038/sj.gt.3302155
Abstract
The long-term goal of the present study is to develop a clinically applicable approach to enhance natural repair mechanisms within cartilage lesions by targeting bone marrow-derived cells for genetic modification. To determine if bone marrow-derived cells infiltrating osteochondral defects could be transduced in situ, we implanted collagen–glycosaminoglycan (CG) matrices preloaded with adenoviral vectors containing various marker genes into lesions surgically generated in rabbit femoral condyles. Analysis of the recovered implants showed transgenic expression up to 21 days; however, a considerable portion was found in the synovial lining, indicating leakage of the vector and/or transduced cells from the matrix. As an alternative medium for gene delivery, we investigated the feasibility of using coagulated bone marrow aspirates. Mixture of an adenoviral suspension with the fluid phase of freshly aspirated bone marrow resulted in uniform dispersion of the vector throughout, and levels of transgenic expression in direct proportion to the density of nucleated cells in the ensuing clot. Furthermore, cultures of mesenchymal progenitor cells, previously transduced ex vivo with recombinant adenovirus, were readily incorporated into the coagulate when mixed with fresh aspirate. These vector-seeded and cell-seeded bone marrow clots were found to maintain their structural integrity following extensive culture and maintained transgenic expression in this manner for several weeks. When used in place of the CG matrix as a gene delivery vehicle in vivo, genetically modified bone marrow clots were able to generate similarly high levels of transgenic expression in osteochondral defects with better containment of the vector within the defect. Our results suggest that coagulates formed from aspirated bone marrow may be useful as a means of gene delivery to cartilage and perhaps other musculoskeletal tissues. Cells within the fluid can be readily modified with an adenoviral vector, and the matrix formed from the clot is completely natural, native to the host and is the fundamental platform on which healing and repair of mesenchymal tissues is based.Keywords
This publication has 35 references indexed in Scilit:
- Insulin-like growth factor-I enhances cell-based repair of articular cartilageThe Journal of Bone and Joint Surgery, 2002
- Bone morphogenetic proteins promote cartilage differentiation and protect engineered artificial cartilage from fibroblast invasion and destructionArthritis & Rheumatism, 2002
- BMP‐2 and BMP‐9 promotes chondrogenic differentiation of human multipotential mesenchymal cells and overcomes the inhibitory effect of IL‐1Journal of Cellular Physiology, 2001
- Overexpression of human insulin-like growth factor-I promotes new tissue formation in an ex vivo model of articular chondrocyte transplantationGene Therapy, 2001
- Enhanced repair of extensive articular defects by insulin‐like growth factor‐I‐laden fibrin compositesJournal of Orthopaedic Research, 1999
- Expression of human bone morphogenic protein 7 in primary rabbit periosteal cells: potential utility in gene therapy for osteochondral repairGene Therapy, 1998
- Transplantation of transduced chondrocytes protects articular cartilage from interleukin 1-induced extracellular matrix degradation.JCI Insight, 1995
- Transforming growth factor β1 stimulates type II collagen expression in cultured periosteum-derived cellsJournal of Bone and Mineral Research, 1992
- Healing of experimentally produced lesions in articular cartilage following chondrocyte transplantationThe Anatomical Record, 1987
- Abrasion chondroplastyArthroscopy: The Journal of Arthroscopic & Related Surgery, 1986